

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Delorme, *et al.*

(Cont. of Appl. No.: 10/222,990)

Filed: herewith

Appl. No.: to be assigned

For: Novel Compounds with Analgesic Effect

Art Unit: to be assigned
(1625 in parent case)Examiner: to be assigned
(E. Huang in parent case)

Atty. Dkt.: 7567/80916

**General Authorization for Petition for
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**

Commissioner of Patents
U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, MS Patent Application
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:


Applicants hereby request under 37 C.F.R. §1.136(a)(3) by this general authorization that any concurrent or future reply submitted by Applicants to the United States Patent and Trademark Office for the above-identified patent application requiring a petition for an extension of time under §1.136(a) for its timely submission be treated as incorporating therein a petition for an extension of time for the appropriate length of time.

If Applicants do not timely pay for any extension fee(s) pursuant to 37 C.F.R. §1.136(a) which may become due for this application under 37 C.F.R. §1.17 by check, the Director is hereby authorized to charge such fee(s), and any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7567/80916.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By



Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

Date December 9, 2003
1801 K Street, N.W., Suite 401L
Washington, DC 20006-1201
Phone: (202) 419-7013

**Facsimile****RECEIVED
CENTRAL FAX CENTER**

JUN 15 2005

Date: June 15, 2005
Fax No.: 703-872-9306
To: USPTO
Art Unit: 1625
Appln. No.: 10/730,265
Filing Date: December 9, 2003
Docket No.: A1570-4P US
Title: Compounds with Analgesic Effect
From: Jianzhong Shen
Customer No.: 22466


No. of Pages: 17
(including this one)

If transmission is not complete or is illegible, please contact me at 302-885-0091.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that the following correspondence is being facsimile transmitted to the United States Patent and Trademark office on: June 15, 2005

Liz Ashton
Typed or Printed Name


Signature

Attachments

- 1) Revocation of POA with New POA and Change of Correspondence Address
- 2) Statement under 37 CFR 3.73(b)
- 3) Copy of Recorded Assignments

Information contained in this fax may be confidential and/or legally privileged. This fax is intended to be reviewed initially by only the individual or legal entity named above. If the reader of this transmittal page is not the intended recipient or a representative of the intended recipient, you are hereby notified that any reading, dissemination or copying of this fax or the information contained herein is prohibited. If you have received this fax in error please immediately notify the sender by telephone and return this fax to the sender at the address below. Thank you.

AstraZeneca
Global Intellectual Property
1800 Concord Pike
Wilmington DE-19850-5437

Tel: +1 302 886 3000
Fax: +1 302 886 8221
www.astrazeneca-us.com

AstraZeneca Pharmaceuticals LP
1800 Concord Pike
Wilmington, Delaware 19850-5438
USA